BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Investor ignorance is what dropped the price. Many thought BPAX was a one drug company, Libigel. It had a set back when the placebo (which by the way looks like it was steroids) did as well as Libigel in the sexual satisfactory events. The rest of the pipeline did not exist. This was not helped by the uneducated postings of some Seeking Alpha bloggers and Adam Feuerstein of the Street.com and ambulance chasing law firms. If any of them had evaluated the company and did their due diligence and actually compare them to their competitors they would have realized it was grossly undervalued at $2.50, let alone $0.40.

Know what you are investing in. This way you never hold onto it too long or get rid of it too early.